Dr. Danesh A. Alam, MD
Psychiatry (Psychiatry Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Illinois since 1999, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
FL license ME97712 · IL license 036-101113 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trazodone Hcl Other prescribers in Winfield, IL | 21 |
| Fluoxetine Hcl Other prescribers in Winfield, IL | 17 |
| Suboxone (buprenorphine hcl/naloxone hcl) Other prescribers in Winfield, IL | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $16,767 in total to this clinician.
| Eli Lilly and Company | $11,219 |
|---|---|
| Janssen Pharmaceuticals, Inc | $5,460 |
| E.r. Squibb & Sons, L.l.c. | $51.03 |
| Indivior Inc. | $37.22 |
| Consulting Fee | $16,679 |
|---|---|
| Food and Beverage | $88.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Jul 2, 2025 | Consulting Fee | $11,219 |
| Janssen Pharmaceuticals, Inc Jan 3, 2025 | Consulting Fee SPRAVATO · Neuroscience | $5,460 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $131,175 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD)…
Janssen Research & Development, LLC - A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5
Janssen Research & Development, LLC - A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inade…
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - An open-label, multicenter trial to assess the safety and tolerability of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309 - A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [D6-dm]/quinidine sulfate [q]) for the treatment…
Otsuka Pharmaceutical Development & Commercialization, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.